Nanobac Historical Income Statement

NNBP Stock  USD 0.0001  0.00  0.00%   
Historical analysis of Nanobac Pharmaceuticals income statement accounts such as Gross Profit of 3.4 K can show how well Nanobac Pharmaceuticals Incorporated performed in making a profits. Evaluating Nanobac Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Nanobac Pharmaceuticals's future profits or losses.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Nanobac Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Nanobac Pharmaceuticals is a good buy for the upcoming year.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nanobac Pharmaceuticals Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

About Nanobac Income Statement Analysis

Nanobac Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Nanobac Pharmaceuticals shareholders. The income statement also shows Nanobac investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Nanobac Pharmaceuticals Income Statement Chart

At this time, Nanobac Pharmaceuticals' Research Development is relatively stable compared to the past year. As of 12/11/2024, Total Operating Expenses is likely to grow to about 4.1 M, while Gross Profit is likely to drop 3,389.

Total Revenue

Total revenue comprises all receipts Nanobac Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Nanobac Pharmaceuticals Incorporated minus its cost of goods sold. It is profit before Nanobac Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Cost Of Revenue

Cost of Revenue is found on Nanobac Pharmaceuticals income statement and represents the costs associated with goods and services Nanobac Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.
Most accounts from Nanobac Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Nanobac Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nanobac Pharmaceuticals Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
At this time, Nanobac Pharmaceuticals' Research Development is relatively stable compared to the past year. As of 12/11/2024, Total Operating Expenses is likely to grow to about 4.1 M, while Gross Profit is likely to drop 3,389.
 2010 2011 2023 2024 (projected)
Gross Profit8K3.1K3.6K3.4K
Total Revenue12K17.6K15.9K15.1K

Nanobac Pharmaceuticals income statement Correlations

Nanobac Pharmaceuticals Account Relationship Matchups

Additional Tools for Nanobac Stock Analysis

When running Nanobac Pharmaceuticals' price analysis, check to measure Nanobac Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobac Pharmaceuticals is operating at the current time. Most of Nanobac Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Nanobac Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobac Pharmaceuticals' price. Additionally, you may evaluate how the addition of Nanobac Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.